Predicting atezolizumab response in metastatic urothelial carcinoma patients using machine learning on integrated tumour gene expression and clinical data
Abstract Atezolizumab is a treatment for metastatic urothelial carcinoma (mUC), yet only 23% of mUC patients benefit from it. Worse yet, accurately predicting such responders remains challenging, despite existing biomarkers. Here we employed eight machine learning (ML) algorithms to predict mUC pati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00969-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!